26KIT
CamAPS now on iOS
'Game changing' Cam APS artificial pancreas app now
available on iOS in the UK.
CamDiab, in collaboration
with Ypsomed, has
launched the iOS version of
the mylife CamAPS FX app
in the UK, marking the first time
users in England, Scotland, Wales
and Northern Ireland can easily
and discreetly manage their mylife
Loop directly from their iPhones. This
is the next wave of the international
rollout of the mylife CamAPS FX app
on iOS, following its pilot launch in
Sweden earlier this year.
Alongside the UK, this phase
will also see the iOS version of the
mylife CamAPS FX app go live in
the Republic of Ireland, Germany,
Denmark, Austria, Norway, Finland
and Luxembourg.
Professor Roman Hovorka,
CamAPS FX creator and Professor of
Metabolic Technology at the Institute
of Metabolic Science and Department
of Paediatrics at the University of
Cambridge, said: "We are thrilled to
bring the mylife CamAPS FX app to
iOS users across the UK." This launch
represents a significant step forward
in making advanced, adaptive
diabetes technology more accessible
and convenient. By enabling people
with Type 1 diabetes to discreetly and
effectively manage their condition
directly from their iPhones, we are
delivering on our commitment to
simplify diabetes care and improve
quality of life. Our collaboration with
Ypsomed continues to empower
users through cutting-edge solutions
that blend seamlessly into everyday
life."
We are
delivering on our
commitment to
simplify diabetes
care and improve
quality of life -
Professor Roman
Hovorka
The adaptive mylife CamAPS
FX algorithm runs on the personal
smartphone and is approved for
people with Type 1 diabetes from
one year of age, including the use
in pregnancy (depending on the
sensor used for continuous glucose
monitoring).
Professor Helen Murphy,
Professor of Medicine (Diabetes and
Antenatal Care) at the University of
East Anglia and Professor of Women's
Health at Kings College London,
added, "CamAPS FX is changing
the landscape of Type 1 diabetes
management before, during and after
pregnancy. The iOS rollout means
that even more women can benefit
from this life-changing technology,
which improves maternal glucose
levels, reduces birth complications
and will save babies lives."
The mylife CamAPS FX algorithm is
combined with the mylife YpsoPump
insulin pump and with a sensor for
continuous glucose monitoring, either
with the FreeStyle Libre 3 or the
FreeStyle Libre 3 Plus from Abbott or
the Dexcom G6 from Dexcom.
Professor Partha Kar, Type 1
Diabetes and Tech lead for NHS
England also said, "The launch of
CamAPS FX on iOS is an important
step in expanding access to safe,
evidence-based digital health
solutions for people living with type
1 diabetes. It also reflects the UK's
position as a global leader in driving
inclusive, tech-enabled healthcare
through strong academic, clinical,
and industry collaboration."
CamDiab Ltd is a digital health
company focused on the design,
development, and commercialisation
of its world leading, interoperable
CamAPS FX closed loop app.
www.camdiab.com